Navigation Links
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Date:4/7/2013

l development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. 

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential of NKTR-214 and the value and potential of our technology and drug candidates in our research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
3. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
9. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
10. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... According to a new market research report " ... Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables (Indicators, ... to 2020", published by MarketsandMarkets, The Sterilization Equipment Market is ... a CAGR of 7.6%.from 2015 to 2020. ... ables and 37 F igures ...
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... DANBURY, Conn., Sept. 22, 2011 Biodel Inc. (Nasdaq: ... President and Chief Executive Officer, will be presenting at the ... Hotel in New York.  The presentation is scheduled for Tuesday, ...  To listen to the live webcast or a replay of ...
... 22, 2011 Reportlinker.com announces that ... available in its catalogue: ... Packaging: Global Markets ... REPORT HIGHLIGHTS * ...
Cached Medicine Technology:Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 2Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 3Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 4Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 5Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 6Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 7Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 8Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 9Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 10Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 11Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 12Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 13Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 14Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 15Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 16Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 17Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 18Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 19Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 20Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 21Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 22
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... research firm, has been recognized in the 2015 Aster Awards national competition for ... healthcare organization serving Ocean City and surrounding communities in Coastal Maryland and Southern ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® ... women experienced spontaneous migration of their Implanon® implants, inability to locate the implants, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby sports physiotherapy clinic, ... the understanding and treatment of ankle sprains. A common sports injury, ankle sprains ... be dangerous if the condition augments and causes more disruption. Absolute PhysioCare’s blog ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to ... Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based call ... display logic shows the script components to the agent only when wanted, and allows ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... Reporter , THURSDAY, Sept. 9 (HealthDay News) -- In 2000, ... fruit and vegetables people should eat, but a decade later ... those thresholds, health officials said Thursday. In fact, according ... 2009, 67.5 percent of adults ate fruit less than two ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, ... a quick MRI scan could tell doctors if a child,s ... that mental problems are developing. Researchers say the strategy ... to the age-old growth charts that tell pediatricians if kids ...
... This release is available in French . ... The Journal of Sexual Medicine has found that ... women,s chronic vulvovaginal pain may trigger more pain, but also ... took part in the study, conducted by the University of ...
... of the world,s population is infected with Mycobacterium tuberculosis ... of death world-wide. A new discovery, led by a ... of Medicine, offers hope for new approaches to the ... a novel mechanism that may contribute to immune recognition ...
... , THURSDAY, Sept. 9 (HealthDay News) -- A newly developed ... the kinds of medical problems that may face premature infants, ... a computational method to create a score based on factors ... the first three hours after birth. In a new study, ...
... A method that is widely used to predict the risk ... for millions of Americans, according to a study directed by ... the University of California, San Francisco. The method in ... which is used to estimate a patient,s 10-year risk of ...
Cached Medicine News:Health News:Most Americans Still Not Eating Enough Fruits, Veggies 2Health News:Most Americans Still Not Eating Enough Fruits, Veggies 3Health News:Brain Scans Could Spot Developmental Problems in Kids 2Health News:Romantic partner may play role in reducing vulvovaginal pain 2Health News:New dual recognition mechanism discovered in tuberculosis 2Health News:New dual recognition mechanism discovered in tuberculosis 3Health News:New Tool Aims to Predict Problems in Preemies 2Health News:Simplified heart-risk guideline may miscalculate risk for millions 2Health News:Simplified heart-risk guideline may miscalculate risk for millions 3
... Size: 3.0 x 7.5 x ... Scleral Sponge II line designed by ... material is a closed cell sponge ... are soft with rounded edges to ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
... mm. Half oval. The original Scleral Sponge II ... been modified by Dr. Joseph Olk with this ... cell sponge which is non-toxic and non-antigenic. Implants ... intrusion. These implants are packaged sterile and sold ...
Medicine Products: